EP Patent

EP2308841A3 — Phlorizin analogs as SGLT2 inhibitors

Assigned to Lexicon Pharmaceuticals Inc · Expires 2011-10-26 · 15y expired

What this patent protects

Compounds are disclosed that are inhibitors of SGLT2 and thus may be useful for the treatment of diseases and disorders such as diabetes and obesity.

USPTO Abstract

Compounds are disclosed that are inhibitors of SGLT2 and thus may be useful for the treatment of diseases and disorders such as diabetes and obesity.

Drugs covered by this patent

Patent Metadata

Patent number
EP2308841A3
Jurisdiction
EP
Classification
—
Expires
2011-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Lexicon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.